FDA Launches Real-Time Drug Trial Monitoring with AstraZeneca and Amgen

The U.S. Food and Drug Administration (FDA) is initiating a pilot program for real-time monitoring of clinical drug trials, with AstraZeneca and Amgen as the first participants. The agency reports that 45% of drug development time is currently classified as 'dead time'—periods where data is collected but not immediately analyzed. By enabling real-time data access, the FDA aims to reduce this inefficiency, potentially cutting months or even years from the drug approval process. This initiative represents a significant shift from traditional retrospective trial oversight to a more dynamic, data-driven approach. The program will test the feasibility and impact of continuous data streaming and analysis during active trials, with the goal of accelerating the development of new therapies.